TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21264786

Group type: EXPERIMENTAL
Intervention: Brassicaceae vegetables (small-scale 9-day human experiment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Untreated animals
Number of subjects: 0
Study: 18669952

Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 0
Study: 16819563

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 151

Group type: COMPARATOR
Intervention: TAPP and Bassini repairs
Number of subjects: 151
Study: 15638033

Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 10789326

Group type: EXPERIMENTAL
Intervention: Signed reviews
Number of subjects: 408

Group type: COMPARATOR
Intervention: Unsigned reviews
Number of subjects: 408
Study: 9076465

Group type: EXPERIMENTAL
Intervention: SR-alfuzosin 5 mg twice daily
Number of subjects: 390
Study: 7690956

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (160 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3530572

Group type: EXPERIMENTAL
Intervention: Bevantolol, 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol, 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29168446

Group type: EXPERIMENTAL
Intervention: Gown designed for easy removal at the neck with increased skin coverage and snugness of fit at the wrist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard gown (implied control)
Number of subjects: 0
Study: 27018465

Group type: EXPERIMENTAL
Intervention: 6-hour wound dressing removal
Number of subjects: 320

Group type: COMPARATOR
Intervention: 24-hour wound dressing removal
Number of subjects: 320
Study: 24902407

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power brush (Oral-B Professional Care 1000)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sonic power brush (Colgate ProClinical C200)
Number of subjects: 131
Study: 22629214

Group type: EXPERIMENTAL
Intervention: Preference for ventilator support
Number of subjects: 100
Study: 19877824

Group type: EXPERIMENTAL
Intervention: GaAs laser therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 49
Study: 18394060

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (bicycle ergometer for minimum 30 min at each HD session for 3 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No intradialytic exercise (first 3 months)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cessation of exercise (after 3 months of exercise)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (after 3 months of no exercise)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 3 months of exercise vs. 3 months of no exercise
Number of subjects: 19
Study: 16152824

Group type: EXPERIMENTAL
Intervention: Ginkgolide nebulised inhalation 10 mg/ml, twice daily, for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cromlyn sodium nebulised inhalation 20 mg/10 ml, twice daily, for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline 10 ml, twice daily, for 4 weeks
Number of subjects: 0
Study: 14610012

Group type: EXPERIMENTAL
Intervention: PV‐LAJ disconnection combined with cavotricuspid isthmus (CTI) ablation (group 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: PV‐LAJ disconnection alone (group 2)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PV‐LAJ disconnection combined with CTI ablation (group 1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Repeat PV‐LAJ disconnection procedure
Number of subjects: 108
Study: 11052317

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy with omeprazole 20 mg once a day for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with omeprazole 20 mg once a day for three months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: H. pylori-positive dyspeptic patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scintigraphic examination
Number of subjects: 40
Study: 8644692

Group type: EXPERIMENTAL
Intervention: 1000 mg elemental Ca/d as calcium citrate malate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1725016

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 or 5 mg twice daily)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 6339292

Group type: EXPERIMENTAL
Intervention: Halometasone/triclosan cream (0.05% halometasone and 1% triclosan)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Betamethasone dipropionate/gentamicin sulphate cream (0.05% betamethasone dipropionate and 0.1% gentamicin sulphate)
Number of subjects: 265
Study: 31056413

Group type: EXPERIMENTAL
Intervention: Anti-platelet therapy
Number of subjects: 681

Group type: COMPARATOR
Intervention: No anti-platelet therapy
Number of subjects: 681
Study: 30284865

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 39

Group type: COMPARATOR
Intervention: No VR
Number of subjects: 39
Study: 27746557

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ETAG-guided anesthesia (n = 30)
Number of subjects: 60
Study: 25220886

Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self-Management Course (OPSMC)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Feedback of bone density-defined fracture risk (high vs normal risk)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Households with unemployed main financial provider
Number of subjects: 347
Study: 23114000

Group type: EXPERIMENTAL
Intervention: Structured priority-setting consultation by trained intervention GPs
Number of subjects: 317

Group type: COMPARATOR
Intervention: Unstructured consultation by untrained control GPs
Number of subjects: 317
Study: 20977257

Group type: EXPERIMENTAL
Intervention: Solar disinfection of drinking water (SODIS)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Higher motivation (75% or better completion of diarrhea data)
Number of subjects: 718
Study: 18405377

Group type: EXPERIMENTAL
Intervention: Mental practice-based rehabilitation training (six-week, individually tailored therapy regime)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bimanual upper extremity exercises (control group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Mental practice-based rehabilitation training
Number of subjects: 160
Study: 15845431

Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 1389

Group type: COMPARATOR
Intervention: HIV alone
Number of subjects: 1389
Study: 12211224

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid) and Diclofenac (75 mg bid)
Number of subjects: 24
Study: 10761326

Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptive pill (OCs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 80

Group type: COMPARATOR
Intervention: IUD (Control)
Number of subjects: 80
Study: 8797513

Group type: EXPERIMENTAL
Intervention: C-reactive protein quartile 4
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: α1 acid glycoprotein
Number of subjects: 737
Study: 1466576

Group type: EXPERIMENTAL
Intervention: 2 gm dipirone plus 20 mg hyoscine N‐butylbromide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 150 mg flurbiprofen
Number of subjects: 52
Study: 6722830

Group type: EXPERIMENTAL
Intervention: 1 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 9 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Number of subjects: 44
Study: 29248654

Group type: EXPERIMENTAL
Intervention: Coronary CTA+CTP
Number of subjects: 300

Group type: COMPARATOR
Intervention: Coronary CTA
Number of subjects: 300
Study: 27737636

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg) + 2 L PEG (GrB)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo + 2 L PEG (GrA)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg) + 1.5 L PEG (GrC)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg) + 1 L PEG (GrD)
Number of subjects: 442
Study: 25483700

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 0
Study: 23122299

Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist device (LVAD) implantation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 25
Study: 20400899

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 20
Study: 18584505

Group type: EXPERIMENTAL
Intervention: Experimental program (focused review of ITLS and combat casualty care with hands-on procedure training)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as those who did not complete the experimental program)
Number of subjects: 29
Study: 16083996

Group type: EXPERIMENTAL
Intervention: 1/2-PN + GH (n=8)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Full-PN + GH (n=7)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1/2-PN (n=11)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Full-PN (n=9)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 35
Study: 12442956

Group type: EXPERIMENTAL
Intervention: Heliox-driven bronchodilator (HDBD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Air-driven bronchodilator (ADBD)
Number of subjects: 31
Study: 11914308

Group type: EXPERIMENTAL
Intervention: Randomized trials reported in general health care journals
Number of subjects: 5503

Group type: COMPARATOR
Intervention: Trials with fewer than 100 participants
Number of subjects: 5503

Group type: EXPERIMENTAL
Intervention: Trials with 100 participants or more
Number of subjects: 5503
Study: 9809623

Group type: EXPERIMENTAL
Intervention: Pentoxifylline and ciprofloxacin (PC) therapy for 12 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pentoxifylline and ciprofloxacin with dexamethasone (PCD) therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PC therapy
Number of subjects: 43
Study: 7660408

Group type: EXPERIMENTAL
Intervention: Geriatric team using a day hospital facility
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 120
Study: 1974688

Group type: EXPERIMENTAL
Intervention: Formoterol MDI (12 micrograms)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Formoterol MDI (6, 12, and 24 micrograms)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Formoterol MDI (2 X 12 micrograms)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Formoterol MDI (2 X 12 micrograms) during 3-month monotherapy
Number of subjects: 66
Study: 14658

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg and 2 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg and 20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 7083724

Group type: EXPERIMENTAL
Intervention: Oral midazolam (15 mg) in supine position (part A)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Evening dose of midazolam (part C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Morning dose of midazolam (part B)
Number of subjects: 6
Study: 29942127

Group type: EXPERIMENTAL
Intervention: Breezhaler
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Genuair
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ellipta
Number of subjects: 130

Group type: COMPARATOR
Intervention: Demonstration
Number of subjects: 130
Study: 26957849

Group type: EXPERIMENTAL
Intervention: Ultrasound Biomicroscopy (UBM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 10
Study: 24245543

Group type: EXPERIMENTAL
Intervention: Mitral-valve repair
Number of subjects: 251

Group type: COMPARATOR
Intervention: Chordal-sparing replacement
Number of subjects: 251
Study: 23088447

Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA) exposure
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Interferon Beta (IFNB) exposure
Number of subjects: 423

Group type: COMPARATOR
Intervention: Non-exposed pregnancies (NEP)
Number of subjects: 423
Study: 20046179

Group type: EXPERIMENTAL
Intervention: Malarigen Malaria Pf/Pv Antigen Rapid Test (RDT)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Microscopy (Gold Standard)
Number of subjects: 262
Study: 18343245

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg/d + Ezetimibe 10 mg/d
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fluvastatin XL 80 mg/d
Number of subjects: 82
Study: 15860279

Group type: EXPERIMENTAL
Intervention: Superior incision
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Perpendicular relaxing limbal incision
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Nasal incision
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Temporal incision
Number of subjects: 574
Study: 12784090

Group type: EXPERIMENTAL
Intervention: Testosterone 50 mg monthly injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxandrolone at a weekly dose of 0.7 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Testosterone 25 mg monthly injections
Number of subjects: 30
Study: 10573656

Group type: EXPERIMENTAL
Intervention: BCG high dose (0.1 mg/0.1 ml)
Number of subjects: 281161

Group type: EXPERIMENTAL
Intervention: BCG low dose (0.01 mg/0.1 ml)
Number of subjects: 281161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281161
Study: 8824687

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.1 mg kg‐1 intravenously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yohimbine + Naloxone (0.8 mg intravenously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2061684

Group type: EXPERIMENTAL
Intervention: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 21 days (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 28 days (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 35 days (Group C)
Number of subjects: 18
Study: 6340274

Group type: EXPERIMENTAL
Intervention: Graft irradiation (175 rads every other day, total of 525 rads)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard medical management (intravenous methylprednisolone)
Number of subjects: 64
Study: 31587707

Group type: EXPERIMENTAL
Intervention: Work-related medical rehabilitation
Number of subjects: 484

Group type: COMPARATOR
Intervention: Conventional medical rehabilitation
Number of subjects: 484
Study: 30199516

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention, one-on-one telephone-based sessions over 3 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 36
Study: 26769034

Group type: EXPERIMENTAL
Intervention: Parachute
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no parachute)
Number of subjects: 50
Study: 25208590

Group type: EXPERIMENTAL
Intervention: Aspirin intake at bedtime (80 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aspirin intake on awakening (80 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: COX‐1‐independent assays
Number of subjects: 14
Study: 22995531

Group type: EXPERIMENTAL
Intervention: 220 mg dabigatran etexilate
Number of subjects: 5425

Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran etexilate
Number of subjects: 5425

Group type: COMPARATOR
Intervention: Control group (40 mg enoxaparin)
Number of subjects: 5425
Study: 20384537

Group type: EXPERIMENTAL
Intervention: Clinical practice improvement studies (PBE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metasynthesis
Number of subjects: 0
Study: 17823506

Group type: EXPERIMENTAL
Intervention: Pyridoxamine 50 mg twice daily in PYR-206; escalated to 250 mg twice daily in PYR-205/207
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pyridoxamine 250 mg twice daily in PYR-205/207
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pyridoxamine
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 16044787

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12463460

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etanercept (in a 6-month open-label extension)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etanercept (phase 3 trial)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (phase 3 trial)
Number of subjects: 60
Study: 10516691

Group type: EXPERIMENTAL
Intervention: ATG-F
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: TMG
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: OKT-3
Number of subjects: 132
Study: 8934143

Group type: EXPERIMENTAL
Intervention: Nitinol Strecker stents
Number of subjects: 48
Study: 1930808

Group type: EXPERIMENTAL
Intervention: Unclean procedure (experimental group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual clean procedure (control group)
Number of subjects: 42
Study: 7042559

Group type: EXPERIMENTAL
Intervention: Imipramine pamoate (single dose of 150 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Imipramine hydrochloride (divided dose of 150 mg)
Number of subjects: 36
Study: 28884884

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 27530741

Group type: EXPERIMENTAL
Intervention: Ultrasound tight control strategy targeting clinical and imaging remission
Number of subjects: 238

Group type: COMPARATOR
Intervention: Conventional tight control strategy targeting clinical remission
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ultrasound tight control arm
Number of subjects: 238

Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 238
Study: 24083394

Group type: EXPERIMENTAL
Intervention: attitude-plus-anticipated-regret message
Number of subjects: 245

Group type: COMPARATOR
Intervention: attitude-only message
Number of subjects: 245

Group type: COMPARATOR
Intervention: no message exposure
Number of subjects: 245
Study: 21938072

Group type: EXPERIMENTAL
Intervention: Mannooligosaccharides (MOS) 4 g/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 60
Study: 20683465

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich apple (40g providing 1.43g polyphenols per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polyphenol-poor apple (40g providing 0.21g polyphenols per day)
Number of subjects: 30
Study: 18172173

Group type: EXPERIMENTAL
Intervention: Capecitabine (ECX)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (EOX)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Epirubicin and cisplatin plus fluorouracil (ECF)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Epirubicin and oxaliplatin plus fluorouracil (EOF)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Epirubicin and oxaliplatin plus capecitabine (EOX)
Number of subjects: 1002
Study: 15892540

Group type: EXPERIMENTAL
Intervention: Wrist vibration at 80 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: No wrist vibration (control)
Number of subjects: 0
Study: 12610012

Group type: EXPERIMENTAL
Intervention: Carbohydrate with the free amino acid/protein mixture (CHO+PRO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 20
Study: 10343192

Group type: EXPERIMENTAL
Intervention: Intraperitoneal carboplatin (CBP) 350 mg/m2 plus intravenous cyclophosphamide (CTX) 600 mg/m2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous carboplatin (CBP) 350 mg/m2 plus intravenous cyclophosphamide (CTX) 600 mg/m2
Number of subjects: 90
Study: 7548495

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg single dose
Number of subjects: 213
Study: 1900983

Group type: EXPERIMENTAL
Intervention: Inhalation of green coffee extract
Number of subjects: 10

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) pretreatment (80 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Baseline nonspecific airway hyperresponsiveness to methacholine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 10
Study: 7141388

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31861026

Group type: EXPERIMENTAL
Intervention: Valsartan-amlodipine single-pill combination (SPC)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Valsartan and amlodipine combination (Control)
Number of subjects: 476
Study: 28891056

Group type: EXPERIMENTAL
Intervention: Remifentanil target-controlled infusion using the Minto model
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Minto model during hypothermic circulatory arrest
Number of subjects: 56
Study: 25735200

Group type: EXPERIMENTAL
Intervention: Trauma-informed integrative treatment for PTSD/SUD
Number of subjects: 353

Group type: COMPARATOR
Intervention: Active control psychoeducation course on women's health
Number of subjects: 353
Study: 23959519

Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30